(Q34296800)

1 August 2017

The determination and interpretation of the therapeutic index in drug development (English)

1 reference

1 August 2017

Patrick Y Muller

1

1 reference

1 August 2017

Mark N Milton

series ordinal

2

1 reference

1 August 2017

language of work or name

1 reference

31 August 2012

1 reference

Nature Reviews Drug Discovery

1 August 2017

1 reference

1 August 2017

11

1 reference

1 August 2017

10

1 reference

1 August 2017

751-761

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3801

1 August 2017

0 references

cites work

How to improve R&D productivity: the pharmaceutical industry's grand challenge

1 reference

Beyond debacle and debate: developing solutions in drug safety

31 March 2020

1 reference

The role of litigation in defining drug risks

31 March 2020

1 reference

Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety

31 March 2020

1 reference

Drug safety sciences and the bottleneck in drug development

31 March 2020

1 reference

In silico prediction of drug toxicity

31 March 2020

1 reference

In silico models for drug-induced liver injury--current status

31 March 2020

1 reference

Use of transcriptomics in understanding mechanisms of drug-induced toxicity

31 March 2020

1 reference

Genomic and proteomic approaches for predicting toxicity and adverse drug reactions

31 March 2020

1 reference

Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity

31 March 2020

1 reference

Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring

31 March 2020

1 reference

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

31 March 2020

1 reference

Recognition of adverse and nonadverse effects in toxicity studies

31 March 2020

1 reference

α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain

31 March 2020

1 reference

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

31 March 2020

1 reference

Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors

31 March 2020

1 reference

Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development

31 March 2020

1 reference

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

31 March 2020

1 reference

On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex

31 March 2020

1 reference

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development

31 March 2020

1 reference

Large-scale prediction and testing of drug activity on side-effect targets

31 March 2020

1 reference

Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies

31 March 2020

1 reference

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

31 March 2020

1 reference

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

31 March 2020

1 reference

Imatinib mesylate for the treatment of pulmonary arterial hypertension

31 March 2020

1 reference

Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing

31 March 2020

1 reference

The use of C(av) rather than AUC in safety assessment

31 March 2020

1 reference

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure

31 March 2020

1 reference

Managing the challenge of chemically reactive metabolites in drug development.

31 March 2020

1 reference

In vitro safety pharmacology profiling: what else beyond hERG?

31 March 2020

1 reference

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

31 March 2020

1 reference

Native albumin for targeted drug delivery

31 March 2020

1 reference

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists

31 March 2020

1 reference

Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease

31 March 2020

1 reference

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.

31 March 2020

1 reference

In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.

31 March 2020

1 reference

Membrane transporters in drug development

31 March 2020

1 reference

Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics

31 March 2020

1 reference

12 December 2020

International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.

1 reference

12 December 2020

Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins

1 reference

12 December 2020

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist

1 reference

12 December 2020

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3801

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference